RE:RE:RE:RE:RE:RE:RE:RE:No follow throughIn considering Sernova’s history of hanging on to news for dear life, I’d say to write the halt idea off as a “cute” halfwit Matthews stunt. A halt to me would appear cheap as I see it if it’s trial news that is involved. Even if a trial subject was proven to be insulin independent then release the news and Let ‘er Rip.
Maybe be a different story for news of a collaboration if Sernova can negotiate cash out of pharma for the deal.
an opinion